These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28899623)

  • 1. TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
    Chao YL; Anders CK
    Clin Breast Cancer; 2018 Jun; 18(3):e301-e304. PubMed ID: 28899623
    [No Abstract]   [Full Text] [Related]  

  • 2. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
    Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
    Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender-dependent association of
    Ioannou C; Ragia G; Balgkouranidou I; Xenidis N; Amarantidis K; Koukaki T; Biziota E; Kakolyris S; Manolopoulos VG
    Pharmacogenomics; 2021 Jul; 22(11):669-680. PubMed ID: 34100299
    [No Abstract]   [Full Text] [Related]  

  • 4. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
    Dong SQ; Wang TM; Zhang JB; He YQ; Xue WQ; Wu ZY; Yang DW; Cao LJ; Huang JW; Li XZ; Zhang PF; Zheng XH; Jia WH
    Cancer Res Treat; 2021 Jul; 53(3):724-732. PubMed ID: 33285053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
    Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
    Hamzic S; Kummer D; Froehlich TK; Joerger M; Aebi S; Palles C; Thomlinson I; Meulendijks D; Schellens JHM; García-González X; López-Fernández LA; Amstutz U; Largiadèr CR
    Pharmacol Res; 2020 Feb; 152():104594. PubMed ID: 31838077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
    Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unilateral Capecitabine-related Hand-foot Syndrome.
    Matsuda S; Koketsu H; Hayakawa M; Nagata N
    Intern Med; 2015; 54(21):2779. PubMed ID: 26521911
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
    Shahrokni A; Rajebi MR; Harold L; Saif MW
    JOP; 2009 Mar; 10(2):215-20. PubMed ID: 19287123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
    Suto T; Ishiguro M; Hamada C; Kunieda K; Masuko H; Kondo K; Ishida H; Nishimura G; Sasaki K; Morita T; Hazama S; Maeda K; Mishima H; Ike H; Sadahiro S; Sugihara K; Okajima M; Saji S; Sakamoto J; Tomita N
    Int J Clin Oncol; 2017 Jun; 22(3):494-504. PubMed ID: 28078540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
    Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
    Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
    Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
    Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
    Schüll B; Scheithauer W; Kornek GV
    Onkologie; 2003 Dec; 26(6):578-80. PubMed ID: 14709934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unanticipated toxicity to capecitabine.
    Moore S
    Oncol Nurs Forum; 2009 Mar; 36(2):149-52. PubMed ID: 19273404
    [No Abstract]   [Full Text] [Related]  

  • 16. TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy.
    Henríquez-Hernández LA; Pérez LF; Hernández AG; de León AC; Díaz-Chico B; Rosales AM
    Cancer Epidemiol; 2010 Aug; 34(4):490-3. PubMed ID: 20371218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine.
    Janssen JM; Jacobs BAW; Roosendaal J; Derissen EJB; Marchetti S; Beijnen JH; Huitema ADR; Dorlo TPC
    AAPS J; 2021 Jan; 23(1):23. PubMed ID: 33417061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS.
    Balboa-Beltrán E; Duran G; Lamas MJ; Carracedo A; Barros F
    Mayo Clin Proc; 2015 Sep; 90(9):1298-303. PubMed ID: 26210704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
    Huang HY; Jiang ZF; Wang T; Zhang SH; Bian L; Cao Y; Wu SK; Song ST
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):850-3. PubMed ID: 22335952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine-induced cerebellar toxicity and TYMS pharmacogenetics.
    Saif MW
    Anticancer Drugs; 2019 Apr; 30(4):431-434. PubMed ID: 30875351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.